Clinical Trials · NCT00021450
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Enrollment
- 819
- Start date
- Apr 2001
- Locations
- 20 sites, 11 countries
- Primary endpoint
- Biochemical and clinical disease-free survival as measured by Logrank prostate-specific antigen progression every 6 months until year 5, and annually thereafter